[A Case Report of Successful Treatment with Dose-controlled mFOFOX6+Bevacizumab for Metastatic Colorectal Cancer in Patient Receiving Hemodialysis].
Yakugaku Zasshi
; 144(8): 847-852, 2024.
Article
em Ja
| MEDLINE
| ID: mdl-39085061
ABSTRACT
A 65-years-old man undergoing hemodialysis for chronic kidney disease was diagnosed with ascending colon cancer and 3 hepatic metastases. He was administered mFOLFOX6 (reducing the dose to 50%) plus bevacizumab (BEV) therapy. Hemodialysis was performed 4 h after administration of oxaliplatin on day1 and repeated three times a week. No serious adverse events were observed. After 4 courses of chemotherapy, a computer tomography scan showed that the hepatic metastases had reduced. 2 courses of mFOLFOX6 (increasing the dose to 75%) plus BEV therapy were added, he was operated by laparoscopic right hemicolectomy and laparoscopic patrial hepatectomy. He has been in remission for 2 years and 4 months since the surgery. Dose-adjusted chemotherapy with hemodialysis was effective and improve the prognosis of the patient.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Compostos Organoplatínicos
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Leucovorina
/
Diálise Renal
/
Bevacizumab
/
Fluoruracila
/
Neoplasias Hepáticas
Limite:
Aged
/
Humans
/
Male
Idioma:
Ja
Revista:
Yakugaku Zasshi
Ano de publicação:
2024
Tipo de documento:
Article